International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Du, Jiang Huixin, Deng Hao, Huang Gengda, Zhu Yue, Xiao Rong, Chen Gengjia, Zhou Chengzhi
Аннотация
OBJECTIVE: Pneumonia remains a critical global health challenge, with antimicrobial resistance fundamentally reshaping therapeutic paradigms. This study aimed to characterize global trends in pneumonia-related clinical trials and assess the pipeline response to escalating antimicrobial resistance challenges.
METHODS: We conducted comprehensive analysis using the INFORMA Database, searching MeSH terms 'Community-acquired pneumonia' and 'Hospital-acquired pneumonia' while restricting inclusion to bacterial infections. Interventional clinical trials investigating therapeutic agents for bacterial pneumonia were included. Data collection encompassed trial status, primary drugs, mechanisms of action, patient demographics, and completion dates. Statistical analyses included Cochran-Armitage trend tests for temporal patterns, and Chi-square goodness of fit test for age-stratified analyses.
RESULTS: A total of 2,448 pneumonia-related clinical trials were identified across 113 countries from 1991 to 2024. Phase I trials demonstrated pronounced acceleration, increasing from 3.00 trials per year (1991-2000) to 14.82 trials per year (2020-2024). Five therapeutic mechanisms dominated research: cell wall synthesis inhibitors (24.5%), ribosomal subunit inhibitors (13.5%), DNA topoisomerase inhibitors (12.8%), beta-lactamase inhibitors (9.3%), and cell membrane-related mechanisms (7.9%). Agestratified analysis revealed significant disparities, with elderly-specific trials comprising only 2.8% despite higher disease burden.
CONCLUSION: This analysis reveals accelerating early-phase drug development in response to antimicrobial resistance challenges. While traditional mechanisms remain dominant, novel therapeutic approaches demonstrate promising diversification strategies, though critical gaps persist in elderly-specific drug development.
METHODS: We conducted comprehensive analysis using the INFORMA Database, searching MeSH terms 'Community-acquired pneumonia' and 'Hospital-acquired pneumonia' while restricting inclusion to bacterial infections. Interventional clinical trials investigating therapeutic agents for bacterial pneumonia were included. Data collection encompassed trial status, primary drugs, mechanisms of action, patient demographics, and completion dates. Statistical analyses included Cochran-Armitage trend tests for temporal patterns, and Chi-square goodness of fit test for age-stratified analyses.
RESULTS: A total of 2,448 pneumonia-related clinical trials were identified across 113 countries from 1991 to 2024. Phase I trials demonstrated pronounced acceleration, increasing from 3.00 trials per year (1991-2000) to 14.82 trials per year (2020-2024). Five therapeutic mechanisms dominated research: cell wall synthesis inhibitors (24.5%), ribosomal subunit inhibitors (13.5%), DNA topoisomerase inhibitors (12.8%), beta-lactamase inhibitors (9.3%), and cell membrane-related mechanisms (7.9%). Agestratified analysis revealed significant disparities, with elderly-specific trials comprising only 2.8% despite higher disease burden.
CONCLUSION: This analysis reveals accelerating early-phase drug development in response to antimicrobial resistance challenges. While traditional mechanisms remain dominant, novel therapeutic approaches demonstrate promising diversification strategies, though critical gaps persist in elderly-specific drug development.